BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12790515)

  • 1. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.
    Erickson-Viitanen S; Wu JT; Shi G; Unger S; King RW; Fish B; Klabe R; Geleziunas R; Gallagher K; Otto MJ; Schinazi RF
    Antivir Chem Chemother; 2003 Jan; 14(1):39-47. PubMed ID: 12790515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
    Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
    Shi J; McAtee JJ; Schlueter Wirtz S; Tharnish P; Juodawlkis A; Liotta DC; Schinazi RF
    J Med Chem; 1999 Mar; 42(5):859-67. PubMed ID: 10072683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
    Hammond JL; Parikh UM; Koontz DL; Schlueter-Wirtz S; Chu CK; Bazmi HZ; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3930-2. PubMed ID: 16127074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
    Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
    Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
    J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
    Anderson KS
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase.
    Ray AS; Murakami E; Peterson CN; Shi J; Schinazi RF; Anderson KS
    Antiviral Res; 2002 Dec; 56(3):189-205. PubMed ID: 12406504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance.
    Wang J; Jin Y; Rapp KL; Schinazi RF; Chu CK
    J Med Chem; 2007 Apr; 50(8):1828-39. PubMed ID: 17373782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections.
    Otto MJ
    Curr Opin Pharmacol; 2004 Oct; 4(5):431-6. PubMed ID: 15351346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.
    Shi J; Mathew JS; Tharnish PM; Rachakonda S; Pai SB; Adams M; Grier JP; Gallagher K; Zhang H; Wu JT; Shi G; Geleziunas R; Erickson-Viitanen S; Stuyver L; Otto MJ; Watanabe KA; Schinazi RF
    Antivir Chem Chemother; 2003 Mar; 14(2):81-90. PubMed ID: 12856919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
    Painter GR; Almond MR; Mao S; Liotta DC
    Curr Top Med Chem; 2004; 4(10):1035-44. PubMed ID: 15193137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
    Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
    Wirden M; Delaugerre C; Marcelin AG; Ktorza N; Ait Mohand H; Dominguez S; Schneider L; Ghosn J; Pauchard M; Costagliola D; Katlama C; Calvez V
    Antimicrob Agents Chemother; 2004 Feb; 48(2):644-7. PubMed ID: 14742228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
    Hillaireau H; Dereuddre-Bosquet N; Skanji R; Bekkara-Aounallah F; Caron J; Lepêtre S; Argote S; Bauduin L; Yousfi R; Rogez-Kreuz C; Desmaële D; Rousseau B; Gref R; Andrieux K; Clayette P; Couvreur P
    Biomaterials; 2013 Jul; 34(20):4831-8. PubMed ID: 23562054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.